15.03  0.59 (4.09%)		06-18 16:00
Open: 14.8 High: 15.56 Volume: 3,117,265		Pre. Close: 14.44 Low: 14.34 Market Cap: 924(M)

Short term
Mid term
Targets	6-month :	19.52	1-year :	22.8
Resists	First :	16.71	Second :	19.52
Pivot price	14.19
Supports	First :	13.6	Second :	11.67
MAs	MA(5) :	14.06	MA(20) :	14.35
	MA(100) :	14.02	MA(250) :	10.68
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	52.8	D(3) :	44.9
RSI	RSI(14): 55.5
52-week	High :	16.73	Low :	5.67

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CGEM ] has closed below upper band by 32.7%. Bollinger Bands are 40.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	15.57 - 15.63	15.63 - 15.7
Low:	14.19 - 14.25	14.25 - 14.32
Close:	14.91 - 15.01	15.01 - 15.13

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Thu, 18 Jun 2026
CULLINAN THERAPEUTICS INC (CGEM) Stock Chart - ChartMill

Thu, 18 Jun 2026
Cullinan Therapeutics (CGEM) director receives 21,781-share stock option grant - Stock Titan

Thu, 18 Jun 2026
Director David D. Meek granted 25,319 options at Cullinan Therapeutics (CGEM) - Stock Titan

Thu, 18 Jun 2026
Cullinan Therapeutics (CGEM) director awarded 25,319 options at $13.55 strike - Stock Titan

Thu, 11 Jun 2026
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha

Wed, 10 Jun 2026
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases - Slideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	61 (M)
Shares Float	44 (M)
Held by Insiders	0.4 (%)
Held by Institutions	107.8 (%)
Shares Short	7,970 (K)
Shares Short P.Month	8,800 (K)

EPS	-3.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.96
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.6 %
Return on Equity (ttm)	-48.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.91
Qtrly Earnings Growth	0 %
Operating Cash Flow	-179 (M)
Levered Free Cash Flow	-103 (M)

PE Ratio	-4.46
PEG Ratio	0
Price to Book value	2.52
Price to Sales	0
Price to Cash Flow	-5.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.